Mesa Laboratories (NASDAQ:MLAB) Stock Price Passes Above 200-Day Moving Average – What’s Next?

Shares of Mesa Laboratories, Inc. (NASDAQ:MLAB) crossed above its two hundred day moving average during trading on Wednesday . The stock has a two hundred day moving average of $80.01 and traded as high as $91.02. Mesa Laboratories shares last traded at $88.46, with a volume of 135,812 shares.

Analyst Ratings Changes

Several equities analysts have commented on MLAB shares. Wells Fargo & Company upped their price objective on Mesa Laboratories from $83.00 to $94.00 and gave the company an “equal weight” rating in a research report on Wednesday, February 4th. Zacks Research upgraded Mesa Laboratories from a “strong sell” rating to a “hold” rating in a research report on Friday, January 9th. Weiss Ratings reissued a “sell (d)” rating on shares of Mesa Laboratories in a research note on Thursday, January 22nd. Finally, Wall Street Zen upgraded shares of Mesa Laboratories from a “buy” rating to a “strong-buy” rating in a report on Saturday, February 7th. Two investment analysts have rated the stock with a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Reduce” and a consensus price target of $94.00.

Mesa Laboratories Stock Performance

The company has a market cap of $488.30 million, a P/E ratio of 138.22 and a beta of 0.89. The firm has a 50 day moving average of $86.53 and a 200-day moving average of $80.01. The company has a quick ratio of 1.45, a current ratio of 1.94 and a debt-to-equity ratio of 0.86.

Mesa Laboratories (NASDAQ:MLAB) last issued its earnings results on Tuesday, February 3rd. The medical instruments supplier reported $3.07 earnings per share for the quarter, beating analysts’ consensus estimates of $2.41 by $0.66. Mesa Laboratories had a return on equity of 22.02% and a net margin of 1.51%.The business had revenue of $65.13 million during the quarter, compared to analyst estimates of $63.23 million. As a group, sell-side analysts anticipate that Mesa Laboratories, Inc. will post 8 EPS for the current fiscal year.

Mesa Laboratories Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Monday, March 16th. Investors of record on Saturday, February 28th were issued a $0.16 dividend. This represents a $0.64 annualized dividend and a dividend yield of 0.7%. The ex-dividend date was Friday, February 27th. Mesa Laboratories’s payout ratio is presently 100.00%.

Insider Buying and Selling

In other Mesa Laboratories news, Director Mark Christopher Capone bought 1,301 shares of the business’s stock in a transaction on Tuesday, March 10th. The shares were acquired at an average price of $76.35 per share, with a total value of $99,331.35. Following the transaction, the director owned 3,429 shares of the company’s stock, valued at approximately $261,804.15. This trade represents a 61.14% increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Shiraz Shabanali Ladiwala purchased 3,500 shares of Mesa Laboratories stock in a transaction dated Tuesday, March 10th. The stock was acquired at an average price of $72.23 per share, with a total value of $252,805.00. Following the acquisition, the director owned 8,523 shares in the company, valued at approximately $615,616.29. This represents a 69.68% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders acquired a total of 6,116 shares of company stock valued at $452,076 over the last three months. 4.90% of the stock is owned by company insiders.

Hedge Funds Weigh In On Mesa Laboratories

A number of hedge funds and other institutional investors have recently modified their holdings of MLAB. Northwestern Mutual Wealth Management Co. increased its holdings in Mesa Laboratories by 5,366.7% during the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 328 shares of the medical instruments supplier’s stock valued at $26,000 after buying an additional 322 shares during the period. Caitong International Asset Management Co. Ltd purchased a new stake in Mesa Laboratories during the fourth quarter worth $27,000. Farther Finance Advisors LLC boosted its position in Mesa Laboratories by 17,733.3% during the 3rd quarter. Farther Finance Advisors LLC now owns 535 shares of the medical instruments supplier’s stock valued at $36,000 after acquiring an additional 532 shares in the last quarter. CWM LLC boosted its position in Mesa Laboratories by 48.9% during the 3rd quarter. CWM LLC now owns 597 shares of the medical instruments supplier’s stock valued at $40,000 after acquiring an additional 196 shares in the last quarter. Finally, Kestra Advisory Services LLC purchased a new position in shares of Mesa Laboratories in the 4th quarter valued at $55,000. 90.60% of the stock is currently owned by institutional investors.

Mesa Laboratories Company Profile

Mesa Laboratories, Inc (NASDAQ: MLAB) is a global provider of instrumentation products designed for critical process monitoring, testing and calibration. Headquartered in Lakewood, Colorado, the company serves a diverse set of end markets including healthcare, pharmaceutical, food and beverage, energy and industrial sectors. With a focus on precision measurement and validation, Mesa Laboratories helps customers ensure regulatory compliance, product safety and operational efficiency across complex manufacturing and sterilization processes.

The company’s product portfolio encompasses biological and chemical indicators for sterilization process validation, digital data loggers and sensors for environmental monitoring, and optical gas analyzers with sample-conditioning solutions for oil, gas and petrochemical applications.